Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • General meeting
      • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • World Mitochondrial Disease Week 2022
      • World Mitochondrial Disease Week 2021
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Press releases

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
19 August, 2022
Regulatory

Abliva AB Interim Report January – June 2022

SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies
Continue reading
19 August, 2021
Regulatory

Abliva AB Interim Report January – June 2021

Second quarter summary
Continue reading
21 August, 2020
Regulatory

Abliva AB Interim Report January – June 2020

NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
Continue reading
21 August, 2019
Regulatory

NeuroVive Pharmaceutical AB Interim Report January – June 2019

Focus on genetic mitochondrial diseases
Continue reading
21 August, 2018
Regulatory

NeuroVive Pharmaceutical AB Interim report January – June 2018

NeuroVive out-licenses targeted LHON therapy to BridgeBio
Continue reading
17 August, 2017
Regulatory

NeuroVive Pharmaceutical AB Interim report January – June 2017

Strategic in-licensing broadens the project portfolio
Continue reading
18 August, 2016
Regulatory

NeuroVive Pharmaceutical – Interim report January-June 2016

Business operations
Continue reading
19 August, 2015
Regulatory

NeuroVive: Interim Report 1 Jan. 2015 to 31 Jun. 2015

Negative top-line result of phase III study and continued progress in other clinical projects
Continue reading
20 August, 2014
Regulatory

NeuroVive: Interim Report 1 Jan. 2014 to 30 Jun. 2014

NeuroVive's research wins award at international research symposium
Continue reading
23 August, 2013
Regulatory

NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013

Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 - 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (31 ...
Continue reading

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • Partnering
  • BD Contact

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • General meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all